Olema's cash, cash equivalents, and marketable securities totaled $505.4 million at the end of 2025, bolstered by a follow-on public offering that generated $218.5 million in gross proceeds. This financial strength positions Olema well to continue its operational execution and advance its clinical programs.
The company is on track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer. Additionally, Olema has advanced enrollment in the OPERA-02 trial, which evaluates palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer.
Furthermore, Olema has initiated a Phase 1b/2 study of palazestrant in combination with Pfizer’s novel CDK4 inhibitor, atirmociclib, and continues to enroll patients in the Phase 1 clinical study of OP-3136, with initial clinical data expected in Q2 2026. The company is also preparing for its first potential commercial launch in late 2027, marking a significant strategic outlook for the future.
Sean P. Bohen, M.D., Ph.D., President and CEO of Olema, stated, "2025 was a year of strong execution across the business as we advanced palazestrant as a differentiated endocrine therapy across multiple regimens. Our earlier-phase combination studies with palazestrant continue to advance, and we are pleased to have initiated a Phase 1b/2 study with atirmociclib in collaboration with Pfizer."
Overall, Olema's financial results and clinical advancements reflect a positive trajectory, with the potential for significant impact on the treatment landscape for breast cancer. Investors and stakeholders will be closely monitoring the upcoming data releases and the company's strategic developments in the coming months.
